Table 4.
Studies using Immunotherapies for Post-Allo-HCT Relapse.
| Authors | Therapy | DLI/2nd Transplant | Median time to relapse post-allo-HCT (mos) | Median Age | N | %CR/CRi | ORR | OS |
|---|---|---|---|---|---|---|---|---|
| DLI | ||||||||
| Kolb et al. | DLI | 100% | 7.9 (4.3-33.6) | 37 (4-54) | 23 | 22% | Median 248 days in AML/MDS | |
| Schmid et al. | DLI | 100%/8% | 5.5 (0.1-55) | 39 (16-65) | 171 | 35% | 38% | 2-year OS 20% with DLI |
| Kharfan-Dabaja et al. | DLI | 100%/18% | 7.0 (0.7-129) | 49 (19-75) | 281 | 24% | 5-year OS 15% (10-19%) | |
| Immune Checkpoint Inhibitors | ||||||||
| Davids et al. | Ipilimumab | 12 | 33% | 42% | ||||
| Davids et al. | Nivolumab | 10 | 0% | 0% | ||||
| Haploidentical NK Cell Infusion | ||||||||
| Shaffer et al. | NK cell infusion | 3.5 (1-94) | 19 (1.9-55.9) | 8 | 25% | 38% | Median 12.9 months (0.8-65.3 months) | |
| 2nd Allogeneic Transplant | ||||||||
| Kharfan-Dabaja et al. | 2nd Transplant (MUD) | NR/100% | 15 (6-31) | 46 (35-58) | 320 | 2 year OS 31% (26-37%) | ||
| Kharfan-Dabaja et al. | 2nd Transplant (Haplo) | NR/100% | 11 (5-25) | 44(33-53) | 135 | 2-year OS 29% (20-39%) | ||
| Kharfan-Dabaja et al. | 2nd Transplant | 1%/100% | 11.6 (1-152) | 43 (18-67) | 137 | 39% | 5-year OS 19% (12-25%) | |